Furthermore, most patients with a Philadelphia-positive leukemia receive TKI therapy, which can lead to additional mutations in the BCR-ABL fusion protein in order to achieve resistance to the inhibitor, which in turn could lead to new neoantigens naturally presented on the cell surface. This evidence concerns the gene ABL1 and leukemia.